Literature DB >> 2555273

Reactions of adriamycin with microsomal iron and lipids.

G Minotti1.   

Abstract

Iron plays a central role in oxidative injury, reportedly because it catalyzes superoxide- and hydrogen peroxide-dependent reactions yielding a powerful oxidant such as the hydroxyl radical. Iron is also thought to mediate the cardiotoxic and antitumour effects of adriamycin and related compounds. NADPH-supplemented microsomes reduce adriamycin to a semiquinone radical, which in turn re-oxidizes in the presence of oxygen to form superoxide and hence hydrogen peroxide. During this redox cycling membrane-bound nonheme iron undergoes superoxide dismutase- and catalase-insensitive reductive release. Membrane iron mobilization triggers lipid peroxidation, which is markedly enhanced by simultaneous addition of superoxide dismutase and catalase. The results indicate that: i) lipid peroxidation is mediated by the release of iron, yet the two reactions are governed by different mechanisms; and ii) oxygen radicals are not involved in or may actually inhibit adriamycin-induced lipid peroxidation. Microsomal iron delocalization and lipid peroxidation might represent oxyradical-independent mechanisms of adriamycin toxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2555273     DOI: 10.3109/10715768909087936

Source DB:  PubMed          Journal:  Free Radic Res Commun        ISSN: 8755-0199


  4 in total

Review 1.  Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.

Authors:  James H Doroshow
Journal:  Curr Pharm Biotechnol       Date:  2012-08       Impact factor: 2.837

2.  Mitochondrial delivery of doxorubicin by triphenylphosphonium-functionalized hyperbranched nanocarriers results in rapid and severe cytotoxicity.

Authors:  Theodossis A Theodossiou; Zili Sideratou; Maria E Katsarou; Dimitris Tsiourvas
Journal:  Pharm Res       Date:  2013-08-07       Impact factor: 4.200

Review 3.  Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action.

Authors:  Saad Shaaban; Amr Negm; Elsayed E Ibrahim; Ahmed A Elrazak
Journal:  Oncol Rev       Date:  2014-05-28

4.  Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells.

Authors:  Xu Wang; Renjie Hui; Yun Chen; Wentao Wang; Yujiao Chen; Xiaohai Gong; Jian Jin
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.